Expect to enroll approximately 160 subjects and study 3 doses of Haduvio against placebo Primary efficacy endpoint is the relative change in 24-hour cough frequency of Haduvio versus placebo NEW ...

NEW HAVEN, Conn., March 8, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral ...

NEW HAVEN, Conn., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio ...

Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p<0.0001; 27 mg BID p<0.01); a -43.3% placebo ...

Trevi Therapeutics has announced that its Phase IIb CORAL trial of Haduvio in treating idiopathic pulmonary fibrosis (IPF) subjects with chronic cough, will continue with its current sample size ...

NEW HAVEN, Conn., Oct. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral ...

Patients on Haduvio experienced a statistically-significant improvement (p<0.0001) in the patient-reported Leicester Cough Questionnaire at Day 21 (108 mg BID).

Trevi CEO Jennifer Good said: “The River trial demonstrated that Haduvio was highly effective, and worked quickly at the lowest dose tested across a broad range of cough counts. These results ...

Trevi Therapeutics (TRVI) stock tumbled 23% Tuesday post-market after the company reported results from a human abuse potential study of its drug Haduvio. Read more here.

Haduvio met the primary endpoint with a statistically-significant reduction in the objective 24-hour cough frequency of 67% from baseline and 57% on a placebo-adjusted basis (p<0.0001).

NEW HAVEN, Conn., Oct. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral ...